Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)

Jean-Jacques Kiladjian, Jean-Christophe Ianotto, Juliette Soret, Nabih Maslah, Cendrine Chaffaut, Françoise Boyer perrard, Fiorenza Barraco, Viviane Dubruille, Claude Capron, Amandine Tisserand, Valérie Rolland-Neyret, Zineb Ghrieb, Sylvie Chevret, Isabelle Plo, Marie-Hélène Schlageter, Veronique Meignin, Matthieu Resche-Rigon, Bruno Cassinat

Blood (2022) 140 (Supplement 1): 577–578.

https://doi.org/10.1182/blood-2022-156389

Published: 2022

Journal Articles

Distinct Clinico-Molecular Arterial and Venous Thrombotic Scoring Systems for MPN Patients Risk Stratification

Hélène Pasquer, Rafael Daltro De Oliveira, Juliette Soret, Nabih Maslah, Lin-Pierre Zhao, Clemence Marcault, Marine Cazaux, Nicolas Gauthier, Emmanuelle Verger, Nathalie Parquet, William Vainchenker, Emmanuel Raffoux, Stephane Giraudier, Bruno Cassinat, Jean-Jacques Kiladjian, Lina Benajiba

Blood (2022) 140 (Supplement 1): 830–831.

https://doi.org/10.1182/blood-2022-160329

Published: 2022

Journal Articles

Reduced MDM2 and MDM4 Protein, but Not mRNA, Expression Is Associated with More Severe Disease in Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and Chronic Myelomoncytic Leukemia (CMML)

Norman Salomao, Nabih Maslah, Anouk Giulianelli, Louis Drevon, Lorea Aguinaga, Xiaolian Gu, Bruno Cassinat, Stephane Giraudier, Pierre Fenaux, Robin Fahraeus

Blood (2022) 140 (Supplement 1): 3443–3445.

https://doi.org/10.1182/blood-2022-167260

Published: 2022

Journal Articles

Comprehensive Analysis of Mesenchymal Cells from Myeloproliferative Neoplasm (MPN) Patients Reveals the Role of HOXB7 in Myelofibrosis Induction

Saravanan Ganesan, Sarah Awan-Toor, Fabien Guidez, Nabih Maslah, Celine Aoun, Panhong Gou, Chloe Guiguen, Juliette Soret, Odonchimeg Ravdan, Valeria Bisio, Nicolas Dulphy, Marie-Hélène Schlageter, Michele Souyri, Stephane Giraudier, Jean-Jacques Kiladjian, Christine Chomienne, Bruno Cassinat

Blood (2022) 140 (Supplement 1): 3852–3854.

https://doi.org/10.1182/blood-2022-157490

Published: 2022

Journal Articles

JAK Inhibition Mediates Clonal Selection of RAS Pathway Mutations in Myeloproliferative Neoplasms

Blood (2022) 140 (Supplement 1): 795–796.

https://doi.org/10.1182/blood-2022-167719

Published: 2022

Journal Articles

Canonical Thrombopoietin Receptor Mutants in Myeloproliferative Neoplasms Rely Differently on the Extracellular Domain of the Receptor but Share Similar Mechanisms of Inactivation: An Open Field for the Development of New Therapies

Gabriel Levy, Nicolas Papadopoulos, Christian Pecquet, Jean-Philippe Defour, Emilie Leroy, Nabih Maslah, Bruno Cassinat, Steven Smith, Stefan N Constantinescu

Blood (2022) 140 (Supplement 1): 8736–8737.

https://doi.org/10.1182/blood-2022-168663

Published: 2022

Journal Articles

Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms

Blood (2021) 138 (21): 2142–2148.

https://doi.org/10.1182/blood.2020010402

Published: 2021

Includes: Supplemental data

Journal Articles

Genomic Landscape and Clinical Features of Myeloproliferative Neoplasm (MPN) Patients with Auto-Immune and Inflammatory Diseases (AID)

Dikelele Elessa, Lin-Pierre Zhao, Rafael Daltro De Oliveira, Nabih Maslah, Juliette Soret-Dulphy, Emmanuelle Verger, Clemence Marcault, Nathalie Parquet, Pierre Fenaux, Lionel Ades, Emmanuel Raffoux, Stephane Giraudier, Olivier Fain, Bruno Cassinat, Jean-Jacques Kiladjian, Arsene Mekinian, Lina Benajiba

Blood (2021) 138 (Supplement 1): 1496.

https://doi.org/10.1182/blood-2021-152302

Published: 2021

Journal Articles

Chronic Exposure to Cytoreductive Treatment Shapes Clonal Evolution in Myeloproliferative Neoplasms

Lin-Pierre Zhao, Nabih Maslah, Rafael Daltro De Oliveira, Emmanuelle Verger, Juliette Soret-Dulphy, Clemence Marcault, Nathalie Parquet, Christine Dosquet, William Vainchenker, Emmanuel Raffoux, Stephane Giraudier, Jean-Jacques Kiladjian, Bruno Cassinat, Lina Benajiba, Marine Cazaux

Blood (2021) 138 (Supplement 1): 3620.

https://doi.org/10.1182/blood-2021-152622

Published: 2021

Journal Articles

Myeloproliferative Neoplasms (MPN) Clonal Evolution Landscape and Its Impact on Patients' Prognosis

Lin-Pierre Zhao, Marine Cazaux, Nabih Maslah, Rafael Daltro De Oliveira, Emmanuelle Verger, Juliette Soret-Dulphy, Clemence Marcault, Nathalie Parquet, Christine Dosquet, William Vainchenker, Emmanuel Raffoux, Stephane Giraudier, Jean-Jacques Kiladjian, Bruno Cassinat, Lina Benajiba

Blood (2021) 138 (Supplement 1): 317.

https://doi.org/10.1182/blood-2021-149473

Published: 2021

Journal Articles

Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission

Rafael Daltro De Oliveira, MD, Juliette Soret-Dulphy, MD, Lin-Pierre Zhao, MD, Clemence Marcault, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Nathalie Parquet, MD, Emmanuel Raffoux, MD, William Vainchenker, Christine Chomienne, MD PhD, Bruno Cassinat, PharmD, PhD, Lina Benajiba, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-141223

Published: 2020

Journal Articles

NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)

Clemence Marcault, MD, Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Juliette Soret, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Blandine Roux, MSc, Nathalie Parquet, MD, Christine Dosquet, MD, Delphine Rea, MDPhD, Jean-Marc Zini, William Vainchenker, Emmanuel Raffoux, MD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, Lina Benajiba, MD PhD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-136177

Published: 2020

Journal Articles

SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Clemence Marcault, MD, Juliette Soret, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Blandine Roux, MSc, Nathalie Parquet, MD, Christine Dosquet, MD, Delphine Rea, MDPhD, Jean-Marc Zini, MD, William Vainchenker, Emmanuel Raffoux, MD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, MD PhD, Lina Benajiba, MD PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-141296

Published: 2020

Journal Articles

Significant Impact of the Molecular Profile on the Prognosis of Patients with Myeloproliferative Neoplasms and Splanchnic Vein Thromboses

Pierre-Edouard Debureaux, Bruno Cassinat, PharmD, PhD, Juliette Soret-Dulphy, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Pierre-Emmanuel Rautou, MD PhD, Aurelie Plessier, Dominique Valla, Stephane Giraudier, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2019) 134 (Supplement_1): 836.

https://doi.org/10.1182/blood-2019-123775

Published: 2019

Journal Articles

Outcomes of Patients with Myeloproliferative Neoplasms (MPN) after Interferon-Alpha (IFN) Therapy Discontinuation

Juliette Soret, MD, Bruno Cassinat, PharmD, PhD, Sylvie Chevret, MD PhD, Christine Dosquet, MD PhD, Stephane Giraudier, MD PhD, Emmanuelle Verger, PhD, Nabih Maslah, PhD, Nathalie Parquet, MD, Christine Chomienne, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2016) 128 (22): 3106.

https://doi.org/10.1182/blood.V128.22.3106.3106

Published: 2016

NARROW

Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)

Distinct Clinico-Molecular Arterial and Venous Thrombotic Scoring Systems for MPN Patients Risk Stratification

Reduced MDM2 and MDM4 Protein, but Not mRNA, Expression Is Associated with More Severe Disease in Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and Chronic Myelomoncytic Leukemia (CMML)

Comprehensive Analysis of Mesenchymal Cells from Myeloproliferative Neoplasm (MPN) Patients Reveals the Role of HOXB7 in Myelofibrosis Induction

JAK Inhibition Mediates Clonal Selection of RAS Pathway Mutations in Myeloproliferative Neoplasms

Canonical Thrombopoietin Receptor Mutants in Myeloproliferative Neoplasms Rely Differently on the Extracellular Domain of the Receptor but Share Similar Mechanisms of Inactivation: An Open Field for the Development of New Therapies

Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms

Genomic Landscape and Clinical Features of Myeloproliferative Neoplasm (MPN) Patients with Auto-Immune and Inflammatory Diseases (AID)

Chronic Exposure to Cytoreductive Treatment Shapes Clonal Evolution in Myeloproliferative Neoplasms

Myeloproliferative Neoplasms (MPN) Clonal Evolution Landscape and Its Impact on Patients' Prognosis

Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission

NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)

SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

Significant Impact of the Molecular Profile on the Prognosis of Patients with Myeloproliferative Neoplasms and Splanchnic Vein Thromboses

Outcomes of Patients with Myeloproliferative Neoplasms (MPN) after Interferon-Alpha (IFN) Therapy Discontinuation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only